Credit Suisse Group AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSGKF research report →
Price Chart
About the company
Credit Suisse Group AG, a venerable financial institution established in Zurich, Switzerland, in 1856, offers a wide spectrum of financial services on a global scale. Its operations extend across Switzerland, Europe, the Middle East, Africa, the Americas, and Asia Pacific. The firm caters to an extensive and varied clientele, including ultra-high-net-worth, high-net-worth, affluent, and retail individuals, as well as institutional clients such as corporations, small and medium-sized enterprises, external asset managers, financial institutions, commodity traders, pension funds, hedge funds, governments, foundations, endowments, entrepreneurs, and financial sponsors.
- CEO
- Ulrich Korner
- IPO
- 2009
- Employees
- 48,150
- HQ
- Zurich, CH
Get TickerSpark's AI analysis on CSGKF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.51B
- P/E
- -0.28
- PEG
- 0.00
- P/S
- 0.23
- P/B
- 0.04
- EV/EBITDA
- 3.66
- Div Yield
- 6.12%
- Gross Margin
- 100.00%
- Op Margin
- 14.01%
- Net Margin
- -53.10%
- ROE
- -16.40%
- ROIC
- 1.24%
- 52W High
- $6.05
- 52W Low
- $0.81
- 50D MA
- $0.88
- 200D MA
- $2.82
- Beta
- 1.19
- RSI (14)
- 48
- Avg Volume
- 516.65K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
AXA reported a strong Q1 2024 with 6% revenue growth, solid capital generation, and momentum across P&C, Life & Health, and Asset Management, despite dropping the German back-book sale.· May 3, 2024
- Total revenues rose 6% to EUR 34 billion, with growth across P&C, Life & Savings, Health, and Asset Management.
- P&C revenues increased 7%; personal lines rose 6% and commercial lines grew 7% excluding AXA XL Re, with pricing still above loss trends in most areas.
- Life premiums rose 6%, Health premiums rose 7% to EUR 4.8 billion, and Asset Management posted EUR 6 billion of net inflows.
- Solvency II ratio improved to 229%, up 2 points versus full-year 2023, supported by normalized capital generation and higher equity markets.
- Management said the German transaction termination has no impact on plan targets, and AXA Life Europe’s Munich Re deal will free up EUR 250 million of capital.
- results":"AXA said Q1 2024 total revenues increased 6% to EUR 34 billion. P&C revenues were up 7%, with commercial lines up 7% excluding AXA XL Re and personal lines up 6%. Life premiums rose 6%, Health premiums increased 7% to EUR 4.8 billion, Asset Management revenues rose 3%, and average assets under management were up 2% with EUR 6 billion of net flows. The Solvency II ratio was 229%, up 2 points versus full year 2023. Management maintained a full-year nat cat budget of 4.5 points of combined ratio and said Baltimore bridge exposure would be nonmaterial at group level, or less than EUR 100 million before tax. For Life Europe’s VA reinsurance deal with New Re, AXA expects a EUR 20 million annual reduction in underlying earnings from 2024 onward, offset EPS-wise by a EUR 200 million share buyback, and separately said the deal frees up EUR 250 million of capital. Guidance-wise, management said it remains confident in the new strategic plan, expects commercial pricing momentum to stay broadly stable into 2025, and sees U.K. Health returning to normal profitability early in 2025 or by year-end 2024, around EUR 150 million of improvement versus 2023.","ceo":"Alban Nesle emphasized that Q1 was a very good start to the year and consistent with AXA’s February strategic plan. He highlighted broad-based organic growth, disciplined pricing, and active capital management, while stressing that the company is focusing on profitability in softer markets such as North America professional lines. On the German back-book transaction, he framed the termination as a rational outcome of changed market conditions and said AXA is now in a better position to keep the book if needed, while remaining open to a good offer.","cfo":"Management highlighted a strong balance sheet and capital generation, with the Solvency II ratio at 229% and up 2 points versus year-end 2023. The 7-point operating capital generation included a 1-point drag from business growth in SCR, plus 7 points from normalized capital generation, minus 5 points for foreseeable dividends and buybacks, plus 1 point from the RT1 issuance/repurchase mix, and plus 2 points from markets; there was no meaningful boost from nat cat. On capital allocation, AXA said it intends to keep its stock of debt stable over the plan, manage grandfathered debt proactively, and may use some senior debt, with only a couple of points of potential solvency impact. The Munich Re VA reinsurance deal frees up EUR 250 million of capital but reduces underlying earnings by about EUR 20 million per year from 2024.","qanda":"Analysts focused on U.K. motor volume erosion, commercial pricing versus loss trends, casualty reserve trends, the German deal cancellation, Baltimore bridge exposure, and U.K. Health profitability. Management said U.K. motor volumes are down, but not by anything like 40%, because AXA is letting go of worse risks and reducing average premium per policy as it improves risk selection. On commercial pricing, AXA said U.S. professional lines remain soft, but other lines are still above loss trend; it does not expect abrupt market deterioration in 2025. For casualty, management said it has not seen an acceleration in trend and will review reserves again in Q2. On U.K. Health, AXA said pricing and claims-process changes are a transformation, not an instant fix, with further price increases already taken in April.","bull":"The call showed broad-based growth across all major businesses, with pricing discipline still holding in P&C and solid inflows in Asset Management. Capital remains strong at 229% Solvency II, and management sounded confident that the new strategic plan is on track, with several operational levers still contributing to earnings growth.","bear":"The main pressure points were softer U.S. professional lines pricing, lower traditional savings flows, and continued weakness in U.K. motor volume as AXA sheds poorer risks. The German back-book sale falling through also removes expected cash proceeds, and U.K. Health profitability is still a turnaround story that management says will take until early 2025 or year-end 2024 to normalize."}】</final>```json {} ```
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 77.5%
- Shares Outstanding
- 3.95B
- Float Shares
- 3.06B
Our CSGKF coverage
Recent articles, reports, and earnings notes.
No research on CSGKF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CSGKF report →